CTKB Stock Forecast: Cytek Biosciences, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Cytek Biosciences, Inc. hold a median 12-month price target of $7 — +14.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Cytek Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (92): Analysts have, on balance, been raising their forecasts.
Growth (43): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CTKB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CTKB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.4% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Stephens & Co. | Maintains | Overweight | $6.00 → $7.00 |
| 13 May 2026 | Stephens & Co. | Maintains | Overweight | $5.50 → $4.75 |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $6.00 → $5.50 |
| 8 Jan 2026 | TD Cowen | Maintains | Buy | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 28 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 May 2025 | Goldman Sachs | Maintains | Sell | — |
| 19 Mar 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 4 Mar 2025 | Piper Sandler | Maintains | Overweight | — |
| 11 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 13 Aug 2024 | Piper Sandler | Maintains | Overweight | — |
| 13 May 2024 | Piper Sandler | Maintains | Overweight | — |
| 6 Mar 2024 | Piper Sandler | Maintains | Overweight | — |
| 29 Feb 2024 | Goldman Sachs | Maintains | Buy | — |
| 14 Dec 2023 | Stephens & Co. | Initiates | Overweight | — |
| 9 Nov 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 24 Oct 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 16 Oct 2023 | Piper Sandler | Maintains | Overweight | — |
| 19 July 2023 | Raymond James | Initiates | Market Perform | — |
| 11 May 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CTKB.
This page is one stock. Monday covers all of them.
CTKB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CTKB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Cytek Biosciences, Inc. returned +17.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CTKB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.9×
- Price / book
- 2.5×
- EV / EBITDA
- —
Cheaper than 27% of US stocks
Cheaper than 36% of US stocks
- Revenue growth (YoY)
- 1.8%
- Earnings growth (YoY)
- —
- Gross margin
- 58.9%
- Operating margin
- −22.5%
- Net margin
- −39.1%
Higher than 32% of US stocks
Higher than 72% of US stocks
Higher than 22% of US stocks
Higher than 12% of US stocks
- Return on equity
- −23.2%
- Return on assets
- −6.2%
- Dividend yield
- —
Higher than 31% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cytek Biosciences, Inc. has a market value of $826.6M and an enterprise value of $595.3M.
Revenue in the twelve months to 30 June 2026: $206.7M. The latest quarter grew 5.6% year on year.
Net income over the same four quarters: −$80.6M, a −39.0% net margin.
Diluted earnings per share, trailing twelve months: −$0.62.
Free cash flow in the twelve months to 30 June 2026: −$12.2M.
Cytek Biosciences, Inc. spent $63K on share buybacks in the twelve months to 30 June 2026.
forward P/E: 88.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Cytek Biosciences, Inc. employs 703 people — $294K of revenue per employee.
Data provided by Twelve Data
CTKB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CTKB’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Cytek Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CTKB
What is the CTKB stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Cytek Biosciences, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $7.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CTKB stock a buy right now?
Of the 3 analysts covering Cytek Biosciences, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytek Biosciences, Inc. 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CTKB?
As at 21 Nov 2026, Cytek Biosciences, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).
Will CTKB stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +14.4% from the last close, and Ticker Nerd's factor model ranks Cytek Biosciences, Inc. 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CTKB stock forecast for 2030?
No analyst covering Cytek Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTKB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7.5 over the next 12 months.
How has CTKB stock performed over the past year?
Cytek Biosciences, Inc. returned +17.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cytek Biosciences, Inc. do?
Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications. The company’s portfolio centers on its Full Spectrum Profiling technology, which supports high-resolution, high-content, and high-sensitivity analysis of single cells.
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications. The company’s portfolio centers on its Full Spectrum Profiling technology, which supports high-resolution, high-content, and high-sensitivity analysis of single cells. Its current product lineup includes the Aurora and Northern Lights cell analyzers, the Aurora CS cell sorter, and related integrated tools designed to help researchers study complex biological samples. Cytek Biosciences also offers conventional flow and image-based flow cytometry products through its acquired Amnis and Guava businesses, expanding its reach across cell analysis workflows. The company serves life science researchers and clinical laboratories with solutions used in areas such as immunology, cancer research, infectious disease, and inflammatory disease studies. Headquartered in Fremont, California, Cytek Biosciences focuses on providing a comprehensive platform for cell analysis in global research and applied science markets.
CEO Dr. Wenbin Jiang Ph.D. · 703 employees · United States · https://cytekbio.com